Literature DB >> 19002946

The potential of stem cells for the treatment of brain tumors and globoid cell leukodystrophy.

Patrizia Tunici1, Serena Pellegatta, Gaetano Finocchiaro.   

Abstract

Stem cells of different origin are under careful scrutiny as potential new tools for the treatment of several neurological diseases. The major focus of these reaserches have been neurodegenerative disorders, such as Huntington Chorea or Parkinson Disease (Shihabuddin et al., 1999). More recently attention has been devoted to their use for brain repair after stroke (Savitz et al., 2002). In this review we will focus on the potential of stem cell treatments for glioblastoma multiforme (Holland, 2000), the most aggressive primary brain tumor, and globoid cell leukodystrophy (Krabbe disease), a metabolic disorder of the white matter (Berger et al., 2001). These two diseases may offer a paradigm of what the stem cell approach may offer in term of treatment, alone or in combination with other therapeutic approaches. Two kinds of stem cells will be consideredhere: neural stem cells and hematopoietic stem cells, both obtained after birth. The review will focus on experimental models, with an eye on clinical perspectives.

Entities:  

Year:  2003        PMID: 19002946      PMCID: PMC3466696          DOI: 10.1023/A:1024818621377

Source DB:  PubMed          Journal:  Cytotechnology        ISSN: 0920-9069            Impact factor:   2.058


  60 in total

1.  Site-specific migration and neuronal differentiation of human neural progenitor cells after transplantation in the adult rat brain.

Authors:  R A Fricker; M K Carpenter; C Winkler; C Greco; M A Gates; A Björklund
Journal:  J Neurosci       Date:  1999-07-15       Impact factor: 6.167

2.  The PTEN/MMAC1 tumor suppressor phosphatase functions as a negative regulator of the phosphoinositide 3-kinase/Akt pathway.

Authors:  X Wu; K Senechal; M S Neshat; Y E Whang; C L Sawyers
Journal:  Proc Natl Acad Sci U S A       Date:  1998-12-22       Impact factor: 11.205

Review 3.  Balancing function vs. self defense: the CNS as an active regulator of immune responses.

Authors:  M J Carson; J G Sutcliffe
Journal:  J Neurosci Res       Date:  1999-01-01       Impact factor: 4.164

4.  Gene therapy of experimental brain tumors using neural progenitor cells.

Authors:  S Benedetti; B Pirola; B Pollo; L Magrassi; M G Bruzzone; D Rigamonti; R Galli; S Selleri; F Di Meco; C De Fraja; A Vescovi; E Cattaneo; G Finocchiaro
Journal:  Nat Med       Date:  2000-04       Impact factor: 53.440

5.  Promoter-targeted selection and isolation of neural progenitor cells from the adult human ventricular zone.

Authors:  N S Roy; A Benraiss; S Wang; R A Fraser; R Goodman; W T Couldwell; M Nedergaard; A Kawaguchi; H Okano; S A Goldman
Journal:  J Neurosci Res       Date:  2000-02-01       Impact factor: 4.164

Review 6.  Human neural stem cells: isolation, expansion and transplantation.

Authors:  C N Svendsen; M A Caldwell; T Ostenfeld
Journal:  Brain Pathol       Date:  1999-07       Impact factor: 6.508

7.  In vitro expansion of a multipotent population of human neural progenitor cells.

Authors:  M K Carpenter; X Cui; Z Y Hu; J Jackson; S Sherman; A Seiger; L U Wahlberg
Journal:  Exp Neurol       Date:  1999-08       Impact factor: 5.330

8.  p53 gene mutation and ink4a-arf deletion appear to be two mutually exclusive events in human glioblastoma.

Authors:  G Fulci; M Labuhn; D Maier; Y Lachat; O Hausmann; M E Hegi; R C Janzer; A Merlo; E G Van Meir
Journal:  Oncogene       Date:  2000-08-03       Impact factor: 9.867

9.  Neurogenesis in the adult human hippocampus.

Authors:  P S Eriksson; E Perfilieva; T Björk-Eriksson; A M Alborn; C Nordborg; D A Peterson; F H Gage
Journal:  Nat Med       Date:  1998-11       Impact factor: 53.440

10.  Isolation and cloning of multipotential stem cells from the embryonic human CNS and establishment of transplantable human neural stem cell lines by epigenetic stimulation.

Authors:  A L Vescovi; E A Parati; A Gritti; P Poulin; M Ferrario; E Wanke; P Frölichsthal-Schoeller; L Cova; M Arcellana-Panlilio; A Colombo; R Galli
Journal:  Exp Neurol       Date:  1999-03       Impact factor: 5.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.